Methylphenidate "hexal"

Methylphenidate, the active ingredient in Methylphenidate "hexal", is a central nervous system stimulant presented as an oral tablet for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults, and is prescribed by qualified healthcare professionals.

GNH USA supplies Methylphenidate "hexal" as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across all regions, and we adhere to stringent import and export standards to meet local requirements.

Methylphenidate acts on central nervous system pathways involved in attention and wakefulness.

- Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity. - Adult ADHD: enhances focus and executive function in adult patients. - Narcolepsy: decreases excessive daytime sleepiness and cataplexy episodes.

Methylphenidate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Appetite loss: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach upset: nausea, abdominal discomfort. - Increased heart rate: mild tachycardia. - Irritability: mood swings or heightened emotional response.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmias. - Psychiatric symptoms: hallucinations, severe anxiety, or mania. - Growth suppression: notable decrease in height velocity in children. - Allergic reactions: rash, itching, or swelling. - Seizures: rare occurrence of convulsive episodes.

When prescribing Methylphenidate, clinicians should consider several safety precautions to minimize risks. - Cardiovascular assessment: evaluate blood pressure and heart history before initiation. - Psychiatric screening: monitor for pre‑existing mental health disorders or psychosis. - Growth monitoring: regularly track height and weight in pediatric patients. - Drug abuse potential: assess risk of misuse or dependence, especially in adolescents. - Concomitant medications: review for agents that may increase sympathomimetic effects. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Methylphenidate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may enhance sympathomimetic effects. - Antihypertensives: can reduce efficacy of blood pressure control.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may increase methylphenidate plasma levels. - Antacids: may affect absorption timing. - Seizure threshold‑lowering drugs: monitor for increased seizure risk.